

DAVIS POLK & WARDWELL LLP
450 Lexington Avenue
New York, New York 10017
Telephone: (212) 450-4000
Facsimile: (212) 701-5800
Marshall S. Huebner
Benjamin S. Kaminetzky
Eli J. Vonnegut
Darren S. Klein
James I. McClammy
Christopher S. Robertson

*Counsel to the Debtors
and Debtors in Possession*

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., et al.,

Debtors.¹**

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**NOTICE OF FILING OF BLACKLINE OF
DISCLOSURE STATEMENT FOR REVISED FIFTH AMENDED PLAN**

PLEASE TAKE NOTICE that on March 15, 2021, the above-captioned debtors and debtors in possession (collectively, the “**Debtors**”) filed the *Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2487] (the “**Original**

¹ The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Plan”) and the *Disclosure Statement for Chapter 11 Plan for Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2488] (the “**Disclosure Statement for Original Plan**”).

PLEASE TAKE FURTHER NOTICE that on May 7, 2021, the Debtors filed the *Second Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2823] (the “**Second Amended Plan**”) and the *Disclosure Statement for Second Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2825] (the “**Disclosure Statement for Second Amended Plan**”).

PLEASE TAKE FURTHER NOTICE that on May 24, 2021, the Debtors filed the *Third Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2904] (the “**Third Amended Plan**”) and the *Disclosure Statement for Third Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2907] (the “**Disclosure Statement for Third Amended Plan**”).

PLEASE TAKE FURTHER NOTICE that on May 26, 2021, the Debtors filed the *Fourth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2936] (the “**Fourth Amended Plan**”) and the *Disclosure Statement for Fourth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2937] (the “**Disclosure Statement for Fourth Amended Plan**”).

PLEASE TAKE FURTHER NOTICE that on June 2, 2021, the Debtors filed the *Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2967] (the “**Original Fifth Amended Plan**”) and the *Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2969] (the “**Disclosure Statement for Original Fifth Amended Plan**”).

PLEASE TAKE FURTHER NOTICE that on June 3, 2021, the Debtors filed the revised *Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2982] (the “**Revised Fifth Amended Plan**”) and the revised *Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* [D.I. 2983] (the “**Disclosure Statement for Revised Fifth Amended Plan**”).

PLEASE TAKE FURTHER NOTICE that attached hereto as **Exhibit A** is a blackline of the Disclosure Statement for Revised Fifth Amended Plan reflecting changes from the Disclosure Statement for Original Fifth Amended Plan.

PLEASE TAKE FURTHER NOTICE that copies of the Disclosure Statement for Revised Fifth Amended Plan may be obtained free of charge by visiting the website of Prime Clerk LLC at <https://restructuring.primeclerk.com/purduepharma>. You may also obtain copies of any pleadings by visiting the Bankruptcy Court’s website at <http://www.nysb.uscourts.gov> in accordance with the procedures and fees set forth therein.

PLEASE TAKE FURTHER NOTICE that a hearing to consider the adequacy of the information contained in the Disclosure Statement for Fourth Amended Plan (the “**Disclosure Statement Hearing**”) was held **May 26, 2021, at 10:00 a.m. (prevailing Eastern Time)** before the Honorable Robert D. Drain, United States Bankruptcy Judge, United States Bankruptcy Court for the Southern District of New York, 300 Quarropas Street, White Plains, New York 10601 (the “**Bankruptcy Court**”).

PLEASE TAKE FURTHER NOTICE that a supplemental hearing on the Disclosure Statement for Fourth Amended Plan (the “**First Supplemental Hearing**”) was held before the Bankruptcy Court on June 1, 2021, at 3:00 p.m. (prevailing Eastern Time).

PLEASE TAKE FURTHER NOTICE that the Bankruptcy Court found that the Disclosure Statement for Fourth Amended Plan contains sufficient information pursuant to Section 1125(a) of the Bankruptcy Code, subject to certain changes set forth on the record at the Disclosure Statement Hearing and the First Supplemental Hearing.

PLEASE TAKE FURTHER NOTICE that a second supplemental hearing for the sole purpose of considering incremental changes to the Disclosure Statement was held before the Bankruptcy Court on June 2, 2021, at 3:00 p.m. (prevailing Eastern Time) (the “**Second Supplemental Hearing**”).

PLEASE TAKE FURTHER NOTICE that, at the Second Supplemental Hearing, the Bankruptcy Court found that the Disclosure Statement contains sufficient information pursuant to Section 1125(a) of the Bankruptcy Code, subject to certain further changes set forth on the record at the Supplemental Hearing.

PLEASE TAKE FURTHER NOTICE that, to the extent the Debtors make further revisions to the Disclosure Statement for Revised Fifth Amended Plan, the Debtors will file or present further blacklined copies of such revised documents to the Bankruptcy Court.

Dated: June 3, 2021
New York, New York

DAVIS POLK & WARDWELL LLP

By: /s/ Darren S. Klein

450 Lexington Avenue
New York, New York 10017
Telephone: (212) 450-4000
Facsimile: (212) 701-5800
Marshall S. Huebner
Benjamin S. Kaminetzky

Eli J. Vonnegut
Darren S. Klein
James I. McClammy
Christopher S. Robertson

*Counsel to the Debtors
and Debtors in Possession*

Exhibit A

**Blackline of Disclosure Statement for Revised Fifth Amended Plan Against
Disclosure Statement for Original Fifth Amended Plan**